Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:59:07.172Z.
Calculation as of: 2026-10-06T18:59:07.172Z.
Quote observation: 2026-10-06T18:52:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a7bb93a2e834ec7067e9d54c2948749c38dd5402669cdea4977ff55dc99d60c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Valion Bio, Inc.
Market Cap
$9.88M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Valion Bio, Inc. (VBIO) | $9.88M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.82M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.70M | N/A |
| Ainos, Inc. (AIMD)vs › | $9.70M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.10M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.22M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.42M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.41M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
